overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation–Positive Non–Small Cell Lung Cancer With Acquired Resistance to First- or Third
Search Results
Highlights of the NCCN Oncology Research Program
Moving Forward With Expanding to an “All-RAS Mutational Analysis” in Metastatic Colorectal Cancer: Beyond KRAS Mutations
Tanios Bekaii-Saab
The advent of biologic agents such as those that target the epidermal growth factor receptor (EGFR) has favorably impacted outcomes for patients with metastatic colorectal cancer (mCRC). An important downstream component of EGFR is the RAS
Oncology Research Program
Sensitizing EGFR Mutation or Have Never Smoked Principal Investigator: Joseph Treat, MD Condition: Stage IV nonsquamous non–small cell lung cancer Institution: Fox Chase Cancer Center Patients with non–small cell lung cancer (NSCLC) who harbor an EGFR
Highlights of the NCCN Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi Janne, MD
Highlights of the NCCN Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi Janne, MD
Highlights of the NCCN Oncology Research Program
overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor-Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi
CLO23-046: Pooled Outcomes of Anti-BRAF Agents in Advanced Stage Colorectal Cancer
Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha
are suboptimal. Targeted treatment with anti-BRAF agents plus anti-EGFR antibodies/chemotherapy have shown promising results based on a smaller number of studies. Here we report a pooled estimate of clinical activity of anti-BRAF agents plus anti-EGFR
HSR23-092: Real-World Analysis Examining Cost of Early Disease Progression Among Patients With Epidermal Growth Factor Receptor Mutated Metastatic Non–Small Cell Lung Cancer
Nicole Princic, Elizabeth Marrett, Winghan Jacqueline Kwong, Donna McMorrow, Hana Schwartz, and Janakiraman Subramanian
Background: In the US, approximately 25% of patients with NSCLC have an EGFR exon 19 deletion or L858R mutation ( EGFR m) for which tyrosine kinase inhibitors (TKI) have been shown to extend progression-free survival. Data examining the
HSR24-161: Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates Among Patients With Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023
Xiaohan Hu, Yu-Han Kao, Ashwini Arunachalam, Diana Chirovsky, Yiru Wang, Chenan Zhang, Kaitlyn Kane, and Ayman Samkari
Background: The management of resectable early-stage NSCLC in the US has been rapidly evolving since late 2020 when the EGFR tyrosine kinase inhibitor (TKI) osimertinib was approved as adjuvant therapy for resected EGFR-mutated NSCLC. After
Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung Cancer Principal Investigator: Pasi Janne, MD
